Compare AbbVie Inc (ABBV) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs VanEck Junior Gold Miners — how do they compare? AbbVie Inc trades at $248.18 (market cap $441.94B), while VanEck Junior Gold Miners trades at $119.53. The key difference: AbbVie Inc pays a 2.77% dividend while VanEck Junior Gold Miners pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| ABBV | GDXJ | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $263.58 | $156.19 |
52-Week Low | $197.38 | $71.22 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
GDXJ, the VanEck Junior Gold Miners ETF, trades at $119.18, up 0.34% on the day, with a bullish technical signal driven by moving averages but tempered by overbought oscillators. Recent news highlights institutional selling and underperformance versus peers, while the ETF's composition shows less small-cap exposure than advertised. Key support lies at $118, with resistance at $120.
The outlook is mixed: bullish momentum persists near-term, but high RSI readings and negative sentiment from articles like Seeking Alpha (2026-06-24) suggest caution. Risks include gold price volatility and Federal Reserve policy shifts, while institutional activity, such as Amundi's 50.5% stake reduction (Defense World, 2026-08-06), indicates skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
